Bioequivalence of Amoxicillin Sodium and Clavutante Potassium Capsules in Chinese Healthy Volunteers
Bin Deng
Abstract
Bin Deng
Abstract
OBJECTIVE To evaluate the bioequivalence of Amoxicillin sodium and Clavutante Potassium capsules in Chinese healthy volunteers.METHODS Concentrations of Amoxicillin sodium and Clavutante Potassium in plasma were determined by HPLC/MS/MS after healthy volunteers received a single dose of test dispersible capsule and reference capsule in two-treatment,two-period,crossover design.RESULTS The main pharmacokinetic parameters of Amoxicillin sodium and Clavutante Potassium capsules were as follows: AUC0→10(Amoxicillin) were(19.132±4.196) and(19.001±4.076) g·h·mL 1;AUC0→∞(Amoxicillin) were(19.376±4.197) and(19.301±4.086) g·h·mL 1;Cmax(Amoxicillin) were(6.294±1.819) and(6.293±1.973) g·mL 1;Tmax(Amoxicillin) were(2.000±0.585) and(2.100±0.447)h;AUC0→10(Clavutante) were(4.333±2.317) and(4.275±2.231) g·h·mL 1;AUC0→∞(Clavutante) were(4.383±2.320) and(4.320±2.236) g·h·mL 1;Cmax(Clavutante) were(1.722±0.961) and(1.623±0.813) g·mL 1;Tmax(Clavutante) were(1.850±0.651) and(1.950±0.647)h;The relative bioavailability of Amoxicillin sodium and Clavutante Potassium were(101.8±14.8)% and(112.5±62.0)%.CONCLUSION The results of statistic analysis show that two capsules of Amoxicillin sodium and Clavutante Potassium were bioequivalent.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE To evaluate the bioequivalence of Amoxicillin sodium and Clavutante Potassium capsules in Chinese healthy volunteers.METHODS Concentrations of Amoxicillin sodium and Clavutante Potassium in plasma were determined by HPLC/MS/MS after healthy volunteers received a single dose of test dispersible capsule and reference capsule in two-treatment,two-period,crossover design.RESULTS The main pharmacokinetic parameters of Amoxicillin sodium and Clavutante Potassium capsules were as follows: AUC0→10(Amoxicillin) were(19.132±4.196) and(19.001±4.076) g·h·mL 1;AUC0→∞(Amoxicillin) were(19.376±4.197) and(19.301±4.086) g·h·mL 1;Cmax(Amoxicillin) were(6.294±1.819) and(6.293±1.973) g·mL 1;Tmax(Amoxicillin) were(2.000±0.585) and(2.100±0.447)h;AUC0→10(Clavutante) were(4.333±2.317) and(4.275±2.231) g·h·mL 1;AUC0→∞(Clavutante) were(4.383±2.320) and(4.320±2.236) g·h·mL 1;Cmax(Clavutante) were(1.722±0.961) and(1.623±0.813) g·mL 1;Tmax(Clavutante) were(1.850±0.651) and(1.950±0.647)h;The relative bioavailability of Amoxicillin sodium and Clavutante Potassium were(101.8±14.8)% and(112.5±62.0)%.CONCLUSION The results of statistic analysis show that two capsules of Amoxicillin sodium and Clavutante Potassium were bioequivalent.
Key concepts: Bioequivalence, Amoxicillin, Cmax, Bioavailability, Potassium, Pharmacokinetics, Chemistry, High-performance liquid chromatography